Immunome Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+6.63%
vs ±18.3% implied · ×0.36
shaded = implied · ▲▼ = realized
Immunome has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
Immunome Inc.
18.23
SentenceIn January 2024, we entered into an exclusive, worldwide license agreement with Immunome, or the Immunome License Agreement, under which Immunome licensed from us ZPC-21 (now known as IM-1021), a preclinical ROR1 ADC with best-in-class potential, and our proprietary ADC platform technology, or the ADC Assets.
SentenceWe acquired varegacestat from Ayala Pharmaceuticals, Inc., or Ayala, in March 2024.
IMNM 10-Kaccession 0001193125-26-088172
SentenceIn January 2022, Morphimmune entered into a Master License Agreement, or the Purdue License Agreement , with Purdue Research Foundation, or PRF.
IMNM 10-Kaccession 0001193125-26-088172
Linked news
Expected move
Inputs8Q avg ±4.3%·×5.57·rich
straddle ±24.2%
spot 18.21exp Nov 20ATM strike 18ATM straddle 5.18IV 150%